Literature DB >> 22632288

Medetomidine immobilisation and atipamezole reversal in large estuarine crocodiles (Crocodylus porosus) using metabolically scaled dosages.

A Olsson1, D Phalen.   

Abstract

BACKGROUND: Restraint of large estuarine crocodiles is potentially dangerous. Neuromuscular blockers and other immobilising drugs have been used with variable results. Medetomidine has been reported as a reliable, repeatable and reversible immobilisation agent in small estuarine crocodilians. METHODS AND
RESULTS: Two wild and two farmed male animals, between 3.05 and 4.6 m long, were hand-injected into a triceps muscle with a metabolically scaled medetomidine dosage. Immobilisation occurred within 30 min. At the conclusion of the procedures, 70 min after medetomidine administration, three animals were injected with atipamezole IM into the opposite triceps muscle at a dosage based on body surface area. Reversal occurred within 5 min. The fourth animal was intubated prior to reversal of medetomidine and maintained on isoflurane anaesthesia for a gastrotomy. All animals were monitored closely post recovery and then regularly for at least 1 week.
CONCLUSIONS: Medetomidine at a metabolically scaled dosage delivered IM into the forelimb was effective for immobilising large estuarine crocodiles for at least 40 min. Atipamezole administered at a dosage calculated as a function of surface area effectively reversed this immobilisation.
© 2012 The Authors. Australian Veterinary Journal © 2012 Australian Veterinary Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22632288     DOI: 10.1111/j.1751-0813.2012.00907.x

Source DB:  PubMed          Journal:  Aust Vet J        ISSN: 0005-0423            Impact factor:   1.281


  1 in total

1.  Long-term surgical anaesthesia with isoflurane in human habituated Nile Crocodiles.

Authors:  George F Stegmann; Catherine J A Williams; Craig Franklin; Tobias Wang; Michael Axelsson
Journal:  J S Afr Vet Assoc       Date:  2017-02-24       Impact factor: 1.474

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.